Last Updated : November 26, 2024
Details
FilesGeneric Name:
Enzalutamide
Project Status:
Complete
Therapeutic Area:
Genito-urinary cancer (prostate cancer)
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0366-000
Call for patient/clinician input closed:
Biosimilar:
No
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
For the treatment of
patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with
biochemical recurrence at high risk of metastasis (high-risk BCR)
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
| Submission received | 30-Apr-24 |
|---|---|
| Review initiated | 01-May-24 |
| Expert committee meeting (initial) | 19-Sep-24 |
| Draft recommendation posted for stakeholder feedback | 17-Oct-24 |
| End of feedback period | 31-Oct-24 |
| Final recommendation posted | 26-Nov-24 |
| Canada's Drug Agency review report(s) posted | 28-Oct-24 |
Files
Last Updated : November 26, 2024